QuantumBio Inc. Awarded National Institutes of Health Contract to Develop Quantum Mechanics-based NMR Refinement Methodologies
March 12, 2007 Filed in: News
FOR IMMEDIATE RELEASE: Monday, March 12, 2007
CONTACT: Lance M. Westerhoff, 814-235-6908, lance@quantumbioinc.com
State College, PA – March 12, 2007. QuantumBio Inc., headquartered in State College, PA with offices in Gainesville, FL and Lancaster, PA, has been selected to receive a FastTrack Small Business Technology Transfer Grant (STTR) grant from the National Institutes of Health valued at approximately $950,000. Titled “Enhancement and Deployment of the Quantum Mechanical NMR Pose Scoring Method”, the project – under the direction of Dr. Kenneth M. Merz Jr., Professor of Chemistry at the University of Florida and Chief Scientific Officer of QuantumBio Inc. and Dr. Lance M. Westerhoff, General Manager of QuantumBio Inc. − will focus on transitioning the novel, quantum mechanically based NMR refinement technologies recently developed in the Merz laboratory to QuantumBio’s product line.
The Phase I STTR project, which began this past fall, expanded on the early, academic development of the methodology and added technologies more applicable to the pharmaceutical and biotechnology industries. Successful completion of the Phase I research provided a foundation for a two-year research and development effort. Phase II begins immediately, and the results of the project will see the technology validated against real-life problems through QuantumBio’s relationships with its industry partners.
By the conclusion of this research phase, QuantumBio will have further expanded on the development of a user-friendly application for drug discovery through the stronger integration of quantum mechanics-based NMR refinement technologies and QuantumBio’s molecular modeling platform, CHEMIX. Ultimately, the supported projects will lead to next generation molecular modeling tools that will aide pharmaceutical and biotechnology companies in developing more potent, less expensive drugs and drug-like compounds.
About QuantumBio
QuantumBio Inc is accelerating drug discovery efforts by providing pharmaceutical, biotechnology companies and life science research organizations with a next generation of Computer-Assisted Drug Design (CADD) and Computer-Assisted Molecular Modeling (CAMM) solutions based on the increased accuracy and power of quantum mechanics. These solutions include a number of options tailored to each customer’s specific requirements including software licensing, services, and customization. Additional information is available at http://www.quantumbioinc.com or by email sales@quantumbioinc.com.
Note: The project discussed in this press release is sponsored by the National Institutes of Health. The content of this press release does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred.
CONTACT: Lance M. Westerhoff, 814-235-6908, lance@quantumbioinc.com
State College, PA – March 12, 2007. QuantumBio Inc., headquartered in State College, PA with offices in Gainesville, FL and Lancaster, PA, has been selected to receive a FastTrack Small Business Technology Transfer Grant (STTR) grant from the National Institutes of Health valued at approximately $950,000. Titled “Enhancement and Deployment of the Quantum Mechanical NMR Pose Scoring Method”, the project – under the direction of Dr. Kenneth M. Merz Jr., Professor of Chemistry at the University of Florida and Chief Scientific Officer of QuantumBio Inc. and Dr. Lance M. Westerhoff, General Manager of QuantumBio Inc. − will focus on transitioning the novel, quantum mechanically based NMR refinement technologies recently developed in the Merz laboratory to QuantumBio’s product line.
The Phase I STTR project, which began this past fall, expanded on the early, academic development of the methodology and added technologies more applicable to the pharmaceutical and biotechnology industries. Successful completion of the Phase I research provided a foundation for a two-year research and development effort. Phase II begins immediately, and the results of the project will see the technology validated against real-life problems through QuantumBio’s relationships with its industry partners.
By the conclusion of this research phase, QuantumBio will have further expanded on the development of a user-friendly application for drug discovery through the stronger integration of quantum mechanics-based NMR refinement technologies and QuantumBio’s molecular modeling platform, CHEMIX. Ultimately, the supported projects will lead to next generation molecular modeling tools that will aide pharmaceutical and biotechnology companies in developing more potent, less expensive drugs and drug-like compounds.
About QuantumBio
QuantumBio Inc is accelerating drug discovery efforts by providing pharmaceutical, biotechnology companies and life science research organizations with a next generation of Computer-Assisted Drug Design (CADD) and Computer-Assisted Molecular Modeling (CAMM) solutions based on the increased accuracy and power of quantum mechanics. These solutions include a number of options tailored to each customer’s specific requirements including software licensing, services, and customization. Additional information is available at http://www.quantumbioinc.com or by email sales@quantumbioinc.com.
Note: The project discussed in this press release is sponsored by the National Institutes of Health. The content of this press release does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred.